Clinical trials
Metastatic Skin Squamous Cell Carcinoma clinical trials
Below are recruiting metastatic skin squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 285 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07529873RecruitingPhase 2
Study of two drugs for advanced head and neck cancer
This trial tests a combination of two medications, ficerafusp alfa and nivolumab, for people with head and neck cancer that has progressed after platinum-based treatment. The goal is to see if this combination can help control the cancer.
VillejuifAges 18–75 - NCT07115043RecruitingPhase 1/Phase 2
Study of AZD6750 for advanced solid tumors
This trial tests a new drug called AZD6750 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT07564232RecruitingPhase 1
LNK001 for Advanced Kidney Cancer After Prior Treatments
This Phase 1 trial tests a new cell therapy called LNK001 in patients with advanced clear-cell kidney cancer that has progressed despite prior immunotherapy and targeted drugs. The therapy is designed to recognize and attack cancer cells by targeting a protein called CAIX.
Houston, TexasAges 18 years+ - NCT07807163RecruitingPhase 2
Study of ficerafusp alfa with pembrolizumab for head and neck cancer
This study tests a new drug called ficerafusp alfa combined with pembrolizumab (an immunotherapy) in people with head and neck cancer that has returned or spread. The drug targets a protein that may help the immune system fight the cancer. The study is comparing two different schedules of giving the drug to see which is better.
Fort Myers, FloridaAges 18 years+ - NCT07110038RecruitingPhase 2
Study of Enfortumab Vedotin Plus Avelumab for Advanced Penile Cancer
This trial tests a combination of two drugs (enfortumab vedotin and avelumab) as a first treatment for men with advanced or metastatic penile cancer that cannot be removed by surgery. The goal is to see if this new combination can shrink tumors and improve outcomes.
DresdenAges 18 years+ - NCT07042295RecruitingPhase 2
Amivantamab or Cetuximab for Skin Cancer in People with Weakened Immune Systems
This trial tests two drugs, amivantamab with hyaluronidase or cetuximab, in people with weakened immune systems who have advanced skin cancer (squamous cell carcinoma). The goal is to see if these treatments can help shrink or control the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07195734RecruitingPhase 2
Adding chemo or immunotherapy before surgery for advanced head and neck cancer
This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.
Tucson, ArizonaAges 18 years+ - NCT07445048RecruitingPhase 3
Radiation, targeted therapy, and immunotherapy for high-risk head and neck cancer
This trial tests if adding a targeted drug (nimotuzumab) and an immunotherapy (benmelstobart) after surgery and radiation can help prevent cancer from returning in patients with high-risk head and neck cancer who cannot take cisplatin chemotherapy.
ShanghaiAges 18 years+ - NCT06810895Enrolling by invitation
Immunotherapy plus chemo for recurrent cervical cancer
This trial tests a new immunotherapy drug called cadonilimab (AK104) combined with standard chemotherapy for women whose small cell neuroendocrine cervical cancer has returned or spread. The goal is to see if this combination helps shrink tumors or slow the cancer better than chemotherapy alone.
WuhanAges 18–75 - NCT06344052RecruitingPhase 2
SP-002 with Vismodegib for Advanced Basal Cell Cancer
This trial tests a new drug (SP-002) combined with vismodegib for people with locally advanced basal cell carcinoma, a type of skin cancer that can't be treated with surgery or has come back after surgery. The goal is to see if this combination is safe and effective.
Phoenix, ArizonaAges 18 years+ - NCT06118086RecruitingPhase 1/Phase 2
Study of REM-422 for advanced adenoid cystic carcinoma
This trial tests an experimental drug called REM-422 for people with adenoid cystic carcinoma (ACC) that has spread, come back, or cannot be removed by surgery. The study has two parts: an early part for people with advanced ACC and a later part for those with a specific genetic change (MYB biomarker) in their tumor. The goal is to see if REM-422 can slow or stop cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT05733715RecruitingEarly Phase 1
Testing pembrolizumab plus lenvatinib before kidney cancer surgery
This trial tests whether giving pembrolizumab (an immune medicine) and lenvatinib (a targeted medicine) before surgery can shrink or better treat renal cell carcinoma. The goal is to improve surgical outcomes and help the body fight the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07805122Recruiting
Monitoring cabozantinib levels to manage side effects in kidney cancer
This study looks at whether closer monitoring of cabozantinib levels in the blood can help doctors manage side effects better. It's for people with advanced kidney cancer who are already planning to take cabozantinib.
Aviano, PordenoneAges 18 years+ - NCT04370587RecruitingPhase 1/Phase 2
Injecting a cancer medicine into tumors plus pembrolizumab
This Phase 1/2 study tests a medicine injected directly into a tumor, alone or with pembrolizumab (an immune-therapy drug given through a vein). It is for people with advanced or metastatic solid cancers that have grown despite standard treatments, aiming to improve tumor control.
Gilbert, ArizonaAges 18 years+ - NCT06362369RecruitingPhase 1/Phase 2
Oral 7HP349 with immunotherapy for advanced solid tumors
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
Aurora, ColoradoAges 18 years+ - NCT05841472RecruitingPhase 2
Camrelizumab plus chemo for advanced lung cancer without EGFR or ALK
This Phase 2 trial tests whether the immunotherapy drug camrelizumab, combined with pemetrexed and carboplatin, can work better as first treatment for advanced lung cancer that has no EGFR or ALK gene changes. You may be able to join if you have measurable disease, good enough organ function, and meet other safety rules for immune treatment.
AnamAges 19–80 - NCT05307939RecruitingPhase 2
Using tumor DNA tests to time treatment for HPV throat cancer
This study checks a blood test that looks for HPV tumor DNA to help doctors decide when to start routine treatment after surgery. It may help some people avoid starting treatment too early or too late based on how the test changes after the operation.
Miami, FloridaAges 18 years+ - NCT07219576RecruitingPhase 1/Phase 2
Study of Retifanlimab and Ruxolitinib for Certain Cancers
This trial tests a combination of two drugs, retifanlimab and ruxolitinib, for people with advanced kidney cancer (clear cell renal cell carcinoma) or lung cancer (non-small cell lung carcinoma) whose cancer has grown after previous treatment with a type of immunotherapy called PD-1/PD-L1 inhibitors. The goal is to see if this combination can help when standard treatments are no longer working.
La Jolla, CaliforniaAges Any age - NCT07463599RecruitingPhase 1/Phase 2
Tegavivint for advanced colorectal cancer after other treatments
This early-phase trial tests an experimental drug called tegavivint for people with advanced colorectal cancer who have already tried several standard treatments. It aims to see if the drug can shrink or slow the growth of tumors.
Scottsdale, ArizonaAges 18 years+ - NCT04780568RecruitingPhase 1
First-line osimertinib plus tegavivint for EGFR-mutant lung cancer
This Phase 1 study tests osimertinib combined with tegavivint as the first treatment for metastatic (stage IV) non-small cell lung cancer (NSCLC) with certain EGFR gene mutations. It aims to find the safest dose and see how well the combination can control cancer and side effects.
Columbus, OhioAges 18 years+ - NCT05420948RecruitingPhase 2
Pembrolizumab with chemotherapy for returning or spread head cancer
This Phase 2 study tests pembrolizumab (an immunotherapy) plus chemotherapy to treat head and neck cancer that has come back or spread. You might be eligible if standard local treatments won’t be curative and your tumor can be measured on scans.
Chicago, IllinoisAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT06222489RecruitingPhase 2
HER3 PET scan for advanced EGFR-mutant lung cancer
This study uses a special PET/CT scan to measure a protein called HER3 in your tumors. The scan uses a radioactive version of the drug patritumab deruxtecan (HER3-DXd). This test may help doctors understand how much HER3 is in your cancer and decide if HER3-targeted therapy could work for you.
Amsterdam, North HollandAges 18 years+ - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75
Hear when a new Metastatic Skin Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic skin squamous cell carcinoma?
- Yes. Clin2 currently lists 285 recruiting metastatic skin squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic skin squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic skin squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Clear Cell Renal Cell Carcinoma
- Metastatic Head and Neck Squamous Cell Carcinoma
- Squamous Cell Carcinoma of the Skin
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Oropharyngeal Squamous Cell Carcinoma
- Metastatic Hypopharyngeal Squamous Cell Carcinoma
- Metastatic Laryngeal Squamous Cell Carcinoma
- Metastatic Oral Cavity Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.